Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus

BACKGROUND: Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal of th...

Full description

Bibliographic Details
Main Authors:	Clagett, B. (Author), Deeks, S.G (Author), Del Rio, C. (Author), Flexner, C. (Author), Gavegnano, C. (Author), Hardin, W.R (Author), Hunt, P.W (Author), Hurwitz, S.J (Author), Kantor, A. (Author), Lederman, M.M (Author), Lennox, J.J (Author), Marconi, V.C (Author), Moisi, D. (Author), Moser, C. (Author), Overton, E.T (Author), Schinazi, R.F (Author), Sekaly, R.-P (Author), Tressler, R. (Author), Tsibris, A. (Author)
Format:	Article
Language:	English
Published:	NLM (Medline) 2022
Subjects:	adult Adult controlled study HIV HIV Infections human Human immunodeficiency virus Human immunodeficiency virus infection Humans immune activation inflammation Jak inhibitors nitrile Nitriles pyrazole derivative Pyrazoles pyrimidine derivative Pyrimidines randomized controlled trial reservoir ruxolitinib
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus

Internet

Similar Items